

Imprimis Pharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 18-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

 Phase 3 Clinical..... 11

 Clinical..... 14

 Discovery..... 23

[Return to Table of Contents](#)

Imprimis Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Imprimis Pharmaceuticals Inc
Parent Company Name	Imprimis Pharmaceuticals Inc
Website	http://imprimispharma.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	0
Number of Patents as Owner	0
Number of Patents as Third Party	0
Number of Deals	12
Key Indications	Bacterial eye infection,Bleeding,Fibrosis,Infectious disease,Ocular disease,Ocular inflammation,Pain,Penile induration,Wound healing
Key Target-based Actions	Adrenoceptor agonist,Cyclooxygenase inhibitor
Key Technologies	Small molecule therapeutic,Parenteral formulation unspecified,Dermatological formulation,Drug combination,Emulsion dermatological,Freeze drying,Injectable formulation,Ophthalmic formulation,Transdermal formulation

COMPANY PROFILE

SUMMARY

Imprimis Pharmaceuticals Inc (formerly Transdel Pharmaceuticals) aims to develop and commercialize non-invasive topical therapeutics. In January 2009, the company planned to expand its business to include topical cosmetics and cosmeceuticals. In November 2013, Imprimis planned to expand its business to include proprietary formulations in the ophthalmic, wound management, urology and pain therapeutic areas utilizing multiple commercialization pathways, including compounding pharmaceuticals in the US.

In February 2011, the company was considering strategic options such as partnering or collaboration agreements, a merger, equity or debt financing or sale of the company, in order to increase shareholder value and continue development of TDLP-110. The company was consulting two investment banks regarding the strategic alternatives. In June 2011, Cardium Therapeutics agreed to acquire all of Transdel's business assets under Chapter 11 of the US Bankruptcy Code for up to \$4 million. By April 2012, the company had changed its name to Imprimis Pharmaceuticals.

ACQUISITIONS AND SPIN-OFFS

In February 2014, Imprimis agreed to acquire Pharmacy Creations LLC, a compounding pharmacy based in Randolph, NJ. At that time, the transaction was expected to close on or before March 31, 2014.

In June 2013, the company completed the acquisition of IP rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company; in July 2013, the company reported that the IP rights related to IPI-120 were also acquired from the Buderer Drug company.

In June 2011, Cardium Therapeutics agreed to acquire all of Transdel's business assets under Chapter 11 of the US Bankruptcy Code for up to \$4 million. The deal would include Transdel's topical analgesic, TDLP-110, and royalty-bearing license agreements from the company's cosmeceutical business. The \$4 million would be paid in unregistered Cardium shares priced at a minimum of \$0.50 per share with \$1 million being a contingent value payment to be held in escrow (for five years) pending FDA approval of TDLP-110. Transdel's Ketotransdel and related drug delivery technology assets would be managed by a new wholly owned subsidiary of Cardium whereas its cosmeceutical operations would be transferred to Cardium's MedPodium division. At that time, the transaction was subject to approval by the bankruptcy court. By July 2011, the companies had requested the bankruptcy court approve the sale under Section 363 which would avoid filing a plan subject to approval by creditors and in support of this Transdel's major creditor filed a declaration in favor of the purchase. However, later in July 2011, the creditor opposed the sale, potentially to offer a plan of its own, leading to denial of approval by the court. At that time, Cardium planned to continue to assess its options regarding the acquisition and other business opportunities under consideration. By April 2012, the company had changed its name to Imprimis Pharmaceuticals and received financing. At that time, it was presumed the proposed

[Return to Table of Contents](#)



acquisition had been terminated.

In October 2007, Transdel completed a merger and began trading under 'TDLP' on the OTC Bulletin Board.

LICENSING AGREEMENTS

In June 2009, JH Direct acquired the exclusive worldwide rights to Transdel Pharmaceuticals' anti-cellulite cosmeceutical product which uses Transdel's transdermal delivery system technology, Transdel. Transdel would receive initial royalty advances and a continuing licensing royalty on the worldwide sales.

FINANCIAL

In June 2013, the company was set to join the Russell Microcap Index.

In February 2013, the company planned to raise gross proceeds of \$9.66 million (net proceeds \$8.13 million) from the public offering of 1.84 million shares at a price of \$5.25 each. Underwriters were granted a 45-day option to buy up to 276,000 shares to cover over-allotment. The offering was expected to close on or about February 13, 2013. In connection with this offering, the company completed a 1-for-5 reverse stock split. At that time, share were traded on NASDAQ market. In March 2013, the underwriter MDB Capital Group exercised its over-allotment option to buy an additional 276,000 shares of the company's common stock at \$5.25 each, raising gross proceeds of approximately \$1.45 million and net proceeds of \$1.33 million and bringing the total approximate gross proceeds from the offering to \$11.11 million.

In April 2012, Imprimis raised net proceeds of approximately \$7.95 million in a private placement of stock and three year warrants. Each unit was priced \$0.79 and consisted of one share of common stock and a 25% warrant, to purchase additional common shares of Imprimis at \$1.185 per share. Also, the company had the unilateral right to call for the mandatory exercise of the warrants with 90 days notice to the holders, following Impracor approval. At that time, the company intended to file an application to NASDAQ 'in the coming months', for the listing of its shares.

In April 2010, Transdel raised \$1 million from a private debt financing. The company issued a 2-year senior convertible promissory note with an annual interest rate of 7.5%.

In May 2008, Transdel raised \$4 million from closing a private placement of 1,818,180 shares priced at \$2.20 each and warrants to buy 227,272 shares for \$4.40 or \$5.50 each.

In September 2007, the company raised \$4 million from a stock sale.

In June 2007, the company raised \$1.5 million from a note sale.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	2	0	2
Inflammatory disease	2	0	2
Ocular disease	2	0	2
Neurological disease	1	0	1
Cardiovascular disease	1	0	1
Injury	1	0	1
Andrology	1	0	1
Genitourinary disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Clinical	2
Discovery	2

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	3	0	3
Drug - Funding	1	0	0	0	1
Drug - Asset Divestment	0	0	1	0	1
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	3	0	3
Technology - Delivery/Formulation	3	0	0	0	3

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ketoprofen (topical cream, pain), Imprimis

ketoprofen (topical cream, pain), Imprimis SNAPSHOT

Drug Name	ketoprofen (topical cream, pain), Imprimis
Key Synonyms	ketoprofen;Ketotransdel;Impracor
Originator Company	Imprimis Pharmaceuticals Inc
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Pain
Target-based Actions	Cyclooxygenase inhibitor
Other Actions	Non-steroidal anti-inflammatory;Leukotriene synthesis inhibitor;PG synthesis inhibitor;Analgesic
Technologies	Dermatological formulation;Emulsion dermatological;Small molecule therapeutic;Transdermal formulation
Last Change Date	07-Nov-2013

ketoprofen (topical cream, pain), Imprimis DEVELOPMENT PROFILE

SUMMARY

Imprimis Pharmaceuticals (previously Transdel Pharmaceuticals) is developing a topical cream formulation of the COX-inhibiting NSAID ketoprofen (IPI-110, TDLP-110; Ketotransdel, Impracor), using its Transdel (Accudel) technology, for the potential treatment of pain,. In October 2009, positive data were reported from a phase III trial for acute pain. In April 2012, discussions with the FDA was ongoing for an IND filing and using the 505(b)(2) regulatory pathway. In June 2009, the company planned to pursue FDA approval of the drug for other indications, such as osteoarthritis. In February 2013, phase III trials were expected to be initiated in a 'matter of months' ; in June 2013, these trials were planned in Q3 2013 ; in August 2013, the company expected that the trial would not be initiated in the third quarter of 2013. By September 2011, Transdel was seeking to outlicense the drug to a commercial partner.


ketoprofen (topical cream, pain), Imprimis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Imprimis Pharmaceuticals Inc	Pain	US	Phase 3 Clinical	16-Jun-2008

ketoprofen (topical cream, pain), Imprimis CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
22071-15-4	1
	
Name	Type
ketoprofen	BANN; INN; USAN
NAL-1216	Research Code
ELS-115	Research Code
HKT-500	Research Code
TDT-070	Research Code

ketoprofen (topical cream, pain), Imprimis DRUG NAMES

Names	Type
Impracor	Trade Name
Ketotransdel	Trade Name
ketoprofen (topical cream, pain), Transdel	
IPI-110	Research Code
TDLP-110	Research Code
ketoprofen	INN, BANN, USAN
ketoprofen (topical cream, pain), Imprimis	

ketoprofen (topical cream, pain), Imprimis CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

[Return to Table of Contents](#)

Pain											
0	0	0	3	0	0	0	0	0	0	0	3

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	3	0	0	0	0	0	1	0	4


Phase Definitions

- Phase 3 Clinical**
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)
- Phase 2 Clinical**
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)
- Phase 1 Clinical**
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

ketoprofen (topical cream, pain), Imprimis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Imprimis Pharmaceuticals Inc	1	0	4	0	5
Cato Holding Ltd	1	0	0	0	1
DPT Laboratories	1	0	0	0	1
Novum Pharmaceutical Research Services	1	0	0	0	1
US Government	0	0	1	0	1
PPD Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	3	0	3
Drug - Manufacturing/Supply	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)

IPI-120

IPI-120 SNAPSHOT

Drug Name	IPI-120
Key Synonyms	
Originator Company	Buderer Drug Company
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	Buderer Drug Company
Highest Status	Clinical
Active Indications	Infectious disease;Wound healing;Bleeding
Target-based Actions	Plasmin inhibitor
Other Actions	Fibrinolysis inhibitor;Vulnerary agent
Technologies	Dermatological formulation;Emulsion dermatological;Small molecule therapeutic;Systemic formulation unspecified;Antibiotic;Drug combination
Last Change Date	13-Dec-2013

IPI-120 DEVELOPMENT PROFILE

SUMMARY

Imprimis, following the acquisition of Buderer assets, is developing a topical cream formulation of IPI-120, a novel combination of tranexamic acid (a synthetic derivative of the amino acid lysine) and bacitracin, for the potential treatment of bleeding and infections. Imprimis is also investigating the drug combination for the potential treatment of wound healing.

The company reported that the lower concentration of IPI-120 would also be launched as an OTC. Information related to OTC of IPI-120 were not covered in this record.


IPI-120 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Imprimis Pharmaceuticals Inc	Bleeding	US	Clinical	23-Jul-2013
Imprimis Pharmaceuticals Inc	Infectious disease	US	Clinical	23-Jul-2013
Imprimis Pharmaceuticals Inc	Wound healing	US	Discovery	09-Dec-2013

IPI-120 CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
1197-18-8	1
	
Name	Type
tranexamic acid	INN
Lysteda	Trade Name

IPI-120 DRUG NAMES


Names	Type
tranexamic acid + antibiotic (bleeding), Imprimis	
tranexamic acid + bacitracin (topical cream, bleeding/infectious disease/wound healing), Imprimis	
IPI-120	Research Code

[Return to Table of Contents](#)

IPI-120 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Imprimis Pharmaceuticals Inc	0	0	1	0	1
Buderer Drug Company	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Asset Divestment	1	0	1

moxifloxacin + triamcinolone + vancomycin

moxifloxacin + triamcinolone + vancomycin SNAPSHOT

Drug Name	moxifloxacin + triamcinolone + vancomycin
Key Synonyms	TriMox
Originator Company	Novel Drug Solutions
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	Novel Drug Solutions
Highest Status	Clinical
Active Indications	Bacterial eye infection;Ocular inflammation
Target-based Actions	Glucocorticoid agonist;Peptidoglycan recognition protein inhibitor;DNA gyrase inhibitor;Topoisomerase IV inhibitor
Other Actions	RNA synthesis modulator;Ophthalmological antibacterial;Ocular antiinfective antiinflammatory combination;Steroidal anti-inflammatory;Bacterial cell wall synthesis inhibitor;Bacterial nucleic acid synthesis inhibitor
Technologies	Ophthalmic formulation;Small molecule therapeutic;Parenteral formulation unspecified;Antibiotic;Steroid;Drug combination;Sustained release formulation
Last Change Date	13-Dec-2013

moxifloxacin + triamcinolone + vancomycin DEVELOPMENT PROFILE

SUMMARY

Imprimis Pharmaceuticals, following a drugs acquisition from Novel Drug Solutions, is developing IPI-140, a depot combination of the two compounds, moxifloxacin and triamcinolone (TriMox) or the three compounds, moxifloxacin, triamcinolone and vancomycin, for the potential intraoperative ocular injection treatment of inflammatory diseases and bacterial infections following cataract surgery. By August 2013, clinical development had been underway.

moxifloxacin + triamcinolone + vancomycin DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Imprimis Pharmaceuticals Inc	Bacterial eye infection	US	Clinical	28-Aug-2013
Imprimis Pharmaceuticals Inc	Ocular inflammation	US	Clinical	28-Aug-2013
Novel Drug Solutions	Bacterial eye infection	US	Discontinued	28-Aug-2013
Novel Drug Solutions	Ocular inflammation	US	Discontinued	28-Aug-2013


moxifloxacin + triamcinolone + vancomycin CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	1
	
Name	Type
moxifloxacin + triamcinolone + vancomycin	


CAS Registry Number:	Confidence Level:
151096-09-2	1
	
Name	Type
moxifloxacin	BANN; INN
Avalox	Trade Name
Avelox	Trade Name

CAS Registry Number:	Confidence Level:
124-94-7	1
	

[Return to Table of Contents](#)



Name	Type
triamcinolone	INN

CAS Registry Number:	Confidence Level:
1404-90-6	1



Name	Type
vancomycin	BANN; INN; USAN
Vancocin	Trade Name
NKTR-063	Research Code

CAS Registry Number:	Confidence Level:
	1



Name	Type
IPI-140	Research Code
moxifloxacin + triamcinolone	

[Return to Table of Contents](#)


moxifloxacin + triamcinolone + vancomycin DRUG NAMES

Names	Type
moxifloxacin + triamcinolone	
TriMox	Trade Name
IPI-140	Research Code
moxifloxacin + triamcinolone + vancomycin	

moxifloxacin + triamcinolone + vancomycin DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Imprimis Pharmaceuticals Inc	0	0	2	0	2
Eye Care Northwest	1	0	0	0	1
Novel Drug Solutions	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Patent - Exclusive Rights	2	0	2

[Return to Table of Contents](#)

lidocaine + epinephrine/phenylephrine

lidocaine + epinephrine/phenylephrine SNAPSHOT

Drug Name	lidocaine + epinephrine/phenylephrine
Key Synonyms	Shugarcaine
Originator Company	Imprimis Pharmaceuticals Inc
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Ocular disease
Target-based Actions	Adrenoceptor agonist
Other Actions	Ophthalmological agent;Anti-inflammatory;Local anesthetic
Technologies	Ophthalmic formulation;Small molecule therapeutic;Parenteral formulation unspecified;Freeze drying;Drug combination
Last Change Date	12-Dec-2013

lidocaine + epinephrine/phenylephrine DEVELOPMENT PROFILE

SUMMARY

Imprimis Pharmaceuticals is investigating ophthalmic lyophilized formulation of lidocaine + epinephrine (Shugarcaine) (structure shown) or lidocaine + phenylephrine, for the potential intraoperative ocular injection treatment of eye diseases following eye surgery. In November 2013, development was ongoing.



lidocaine + epinephrine/phenylephrine DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Imprimis Pharmaceuticals Inc	Ocular disease	US	Discovery	12-Nov-2013

lidocaine + epinephrine/phenylephrine CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	1
<div style="display: flex; justify-content: space-around; align-items: center;">   </div>	
Name	Type
lidocaine + epinephrine	


CAS Registry Number:	Confidence Level:
51-43-4	1
<div style="display: flex; justify-content: center; align-items: center;">  </div>	
Name	Type
epinephrine	BANN; INN
EpiPen	Trade Name
G2B-011	Research Code

CAS Registry Number:	Confidence Level:
137-58-6	1
<div style="display: flex; justify-content: center; align-items: center;">  </div>	

[Return to Table of Contents](#)



Name	Type
lidocaine	BANN; INN
Xylocaine	Trade Name
Penles Tape	Trade Name
Endole	Trade Name
Penles	Trade Name
AGK-10003	Research Code
URG-301	Research Code
U-301	Research Code
ARC-2022	Research Code
M-5190	Research Code
NAL-1282	Research Code
NRI-ANA	
SHACT	

CAS Registry Number:	Confidence Level:
59-42-7	1



Name	Type
phenylephrine	INN
phenylepinephrine	
PSD-503	

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	1
<div>   </div>	
Name	Type
lidocaine + phenylephrine	

lidocaine + epinephrine/phenylephrine DRUG NAMES

Names	Type
lidocaine + epinephrine	
lidocaine + epinephrine/phenylephrine	
Shugarcaine	Trade Name
lidocaine + phenylephrine	

[Return to Table of Contents](#)

pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis

pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis SNAPSHOT

Drug Name	pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis
Key Synonyms	
Originator Company	Imprimis Pharmaceuticals Inc
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Fibrosis;Penile induration
Target-based Actions	
Other Actions	Anti-inflammatory;Unspecified drug target
Technologies	Injectable formulation;Small molecule therapeutic;Parenteral formulation unspecified
Last Change Date	12-Dec-2013

pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis DEVELOPMENT PROFILE

SUMMARY

Imprimis Pharmaceuticals is investigating an injectable formulation of pentoxifylline, for the potential treatment of peyronie's disease and fibrosis. In December 2013, development was ongoing.

pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Imprimis Pharmaceuticals Inc	Fibrosis	US	Discovery	09-Dec-2013
Imprimis Pharmaceuticals Inc	Penile induration	US	Discovery	09-Dec-2013

pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis DRUG NAMES

Names	Type
pentoxifylline (injectable, peyronie's disease/fibrosis), Imprimis	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

